Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

@article{Steurer2004AnagrelideFT,
  title={Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.},
  author={Michael A. Steurer and Guenther A. Gastl and Wieslaw-Wiktor Jedrzejczak and Robert Pytl{\'i}k and Werner Lin and Ernst Schloegl and Heinz Gisslinger},
  journal={Cancer},
  year={2004},
  volume={101 10},
  pages={2239-46}
}
BACKGROUND Although the platelet count does not correlate with the rate of thrombosis, there is evidence that a strict control of the platelet count decreases the incidence of thromboembolic complications in essential thrombocythemia. In the current study, the authors evaluated the efficacy and tolerability of anagrelide in thrombocytosis associated with myeloproliferative disorders. METHODS The study cohort comprised 97 patients (n = 69 females, n = 28 males) with a median age of 59 years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Long-term management of thrombocytosis in essential thrombocythaemia

Annals of Hematology • 2008
View 6 Excerpts
Highly Influenced

ESSENTIAl THROMBOCYTHEMIA

Toni Valkovića
2015
View 1 Excerpt

Pharmacological management of essential thrombocythemia.

Expert opinion on pharmacotherapy • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…